IDIBELL on the media
Sleep eight hours benefit the retention of weaker memories
People who sleep fewer hours show less consistency in the neural patterns of the repetitions, showing less memory retention.
Age and male sex, key factors in the risk of mortality after hospital admission due to COVID-19
A study with the participation of IDIBELL adds complete information on the complications and prognosis of the first 4,035 patients with COVID-19 in the country.
A study determines the prevalence of mutations in two polymerases in patients with hereditary cancer
A team from the IDIBELL-ICO Hereditary Cancer group has studied more than 2,800 patients with a possible hereditary cancer to determine the frequency of pathogenic mutations in the corrective region of two polymerases.
Identifying these mutations can facilitate the early diagnosis and the personalized treatment of these patients.
IDIBELL scientists find a compound that extends life span in mice
Regenerative medicine scientists at IDIBELL in collaboration with partners at Ulm University (Germany) have demonstrated that inhibition of Cdc42 with CASIN can pharmacologically extend lifespan.
Anna Veiga, new IDIBELL Ombudsperson
The appointment coincides with the constitution of the Research Integrity Committee (CIR), chaired by the Ombudsperson and including different members of the IDIBELL research community, and the update of the “Guide to Good Practices in Research in Health Sciences”.
Successful participation in the International Papilloma Virus Congress (IPVC2020)
This 33rd edition, now virtual, has been organized by the professional team of the Cancer Epidemiology Research Program (IDIBELL-ICO) and by the IPVC.
A mouse model was used to determine the personalized treatment for a cancer patient
A team from IDIBELL and ICO, using a mouse orthotopic model, conducted a real-time personalized oncology study to test the best therapeutic option to treat a type of relapse sarcoma.
Common immune characteristics found in lung metastases to target future treatments
Lung metastatic tumours have common immune properties, regardless of the origin of the primary tumour.
These results suggest new approximations and contemplate the development of new immunotherapy treatments.
